Université Paris-Saclay, CNRS, Institut Galien Paris-Saclay, 92296, Châtenay-Malabry, France.
Institut Universitaire de France.
Chem Rec. 2021 Jan;21(1):149-161. doi: 10.1002/tcr.202000103. Epub 2020 Oct 28.
Among all neurodegenerative diseases, Alzheimer's Disease (AD) is the most prevalent worldwide, with a huge burden to the society and no efficient AD treatment so far. Continued efforts have been being made towards early and powerful diagnosis of AD, in the hope for a successful set of clinical trials and subsequently AD curative treatment. Towards this aim, detection and quantification of amyloid beta (Aβ) peptides in cerebrospinal fluid (CSF) and other biofluids, which are established and validated biomarkers for AD, have drawn attention of the scientific community and industry over almost two decades. In this work, an overview on our major contributions over 15 years to develop different electrokinetic and microfluidic strategies for Aβ peptides detection and quantification is reported. Accordingly, discussions and viewpoints on instrumental and methodological developments for microscale electrophoresis, microfluidic designs and immuno-enrichment / assays on magnetic beads in microchannels for tracing Aβ peptides in CSF are given in this review.
在所有神经退行性疾病中，阿尔茨海默病（AD）是全球最常见的疾病，给社会带来了巨大的负担，迄今为止尚无有效的 AD 治疗方法。人们一直在努力进行 AD 的早期和有效诊断，以期成功进行一系列临床试验并随后进行 AD 治愈性治疗。为此，近二十年来，人们一直关注检测和定量脑脊液（CSF）和其他生物液中的淀粉样β（Aβ）肽，这些已被确立和验证为 AD 的生物标志物。在这项工作中，我们报告了 15 年来在开发用于检测和定量 Aβ肽的不同电泳和微流控策略方面的主要贡献。因此，本文综述了用于微尺度电泳的仪器和方法学发展、微流控设计以及在微通道中用于磁性珠上免疫富集/测定 CSF 中 Aβ肽的讨论和观点。
